Metarecod

Metarecod Aboca is available in the form of sachets containing granules containing a complex of macromolecules. Each sachet contains 2.5 g of product and is intended for single use, with an easy-to-use presentation. The granules are formulated with NeoPolicaptil Gel Retard, which facilitates gradual release.

Metarecod Aboca is intended for adults and children over 8 years of age and is indicated in the following situations:

• LDL cholesterol levels ≥ 100 mg/dl or HDL < 40 mg/dl (men) and < 50 mg/dl (women).
• Triglycerides ≥ 150 mg/dl.
• Fasting blood sugar > 100 mg/dl or reduced glucose tolerance (140-199 mg/dl).
• Increased abdominal circumference (≥ 94 cm in men and ≥ 80 cm in women).

These conditions are frequently associated with metabolic syndrome and may benefit from Metarecod intervention, given its mechanisms of action aimed at improving the body's metabolic status.

Metarecod sachets should be administered according to the specific instructions.

It is recommended to dissolve the contents of one sachet in half a glass of water and consume before main meals. It is essential that the drink is swallowed quickly, before a gel forms in the glass, followed immediately by another half glass of water.

Beneficial effects may begin to be noticed after the first month of use, but a minimum treatment duration of 3 months is recommended for optimal results.

Metarecod is not recommended for people who are allergic or hypersensitive to any of the product's ingredients, such as Avena sativa or Opuntia ficus indica.

There is also insufficient data to support the use of the product in pregnant or breastfeeding women, which is why a doctor's advice is necessary.

It is important that Metarecod is taken at least 2 hours apart from other medications to avoid possible interference with their absorption.

Important! Any metabolic condition during pregnancy should be monitored by a doctor.

Aboca Metarecod is a product free from synthetic chemicals, which contributes to its high safety profile.

At the start of treatment, mild abdominal discomfort such as flatulence may occur, which generally improves during administration.

There are currently no clear data on interactions with other medicines or food. However, due to the way the product works, its use with certain medicines could be affected.

It is therefore essential that users consult a doctor before using Metarecod with other treatments.

If a higher dose than recommended is taken, it is important to consult a specialist. Although Metarecod has a high safety profile, overdose may cause adverse reactions such as gastrointestinal reactions.

To maintain the integrity of the product, Aboca Metarecod should be stored in a cool, dry place, away from sources of heat and light. Keep out of the reach of children. Observe the expiry date stated on the packaging.

• PubMed, Policaptil Gel Retard in adult subjects with metabolic syndrome: Efficacy, safety and tolerability compared to metformin
• PubMed, Effect of Policaptil Gel Retard on hepatic fat content and fibrosis in adults with metabolic syndrome and type 2 diabetes: A non-invasive approach to MAFLD
• MDPI, Comparison between Policaptil Gel Retard and Metformin by testing temporal changes in patients with metabolic syndrome and type 2 diabetes
• Italian Journal of Food Science, Policaptil Gel Retard® reduces body weight and improves insulin sensitivity in obese subjects